About
Qubit Pharmaceuticals is a quantum-enhanced drug discovery company based in Paris and Boston, founded in 2020. Using hybrid quantum-classical computing through its Atlas platform, the company accelerates pharmaceutical research, running molecular simulations 100,000 times faster than traditional methods and reducing drug candidate screening from 5,000 to 200 compounds. Its technologies include the Hyperion-1 quantum emulator, which simulates 40 qubits, and the FeNNix-Bio1 quantum AI foundation model developed with Sorbonne University. The company operates one of France's largest GPU supercomputers and is advancing 7 therapeutic programs, particularly in oncology and inflammation. In December 2025, in collaboration with Sorbonne University, Qubit Pharmaceuticals published results overturning a theoretical speed limit for quantum molecular calculations. The work executed drug-discovery workloads at up to 123 qubits and 2,000 two-qubit gates, reaching classical precision in hydration-site prediction faster than was previously believed physically possible. Update 2026-01-29: Qubit Pharmaceuticals announced a new method that accelerates Relative Binding Free Energy calculations by 15-30x. Source: https://quantumzeitgeist.com/qubit-pharmaceuticals-rbfe-binding-energy/
Quantum Specifications
| Quantum Focus | hardware |
Key People
Funding History
Backed By
Frequently Asked Questions
Related News
CQT and Qubit Pharmaceuticals Partner to Advance Quantum Drug Discovery
Qubit Pharmaceuticals Aims for Quadratic Speedup in Simulations
Qubit Pharmaceuticals to Collaborate With The Centre For Quantum Technologies in Singapore to Advance Quantum Algorithms For Drug Discovery
Qubit Pharmaceuticals Announces 15-30x Speedup in Relative Binding Free Energy Calculations
Qubit Pharmaceuticals Announces Dual Breakthroughs: Quantum Speedup and 2028 Utility Path for Drug Discovery - Quantum Computing Report
